Figure 5. Forest plots for the pooling of mean differences for the outcome of time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test and for the pooling of odds ratios for secondary efficacy outcomes.

The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. (A) Forest plot for the pooling of MDs for the outcome of time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test. MD < 0 indicates beneficial treatment effects of LPV/r compared with the control groups. (B) Forest plot for the pooling of ORs for incidences of positive-to-negative nucleic acid test conversions at day 7. (C) Forest plot for the pooling of ORs for incidences of positive-to-negative nucleic acid test conversions at day 14. OR >1 indicates beneficial treatment effects of LPV/r compared with the control groups for all secondary efficacy outcomes.

LPV/r: Lopinavir–ritonavir; MD: Mean difference; OR: Odds ratio.